Document is current
Any future updates will be listed below
-
Authors
Bolsewig, Katharina https://orcid.org/0000-0003-3116-7789
Willemse, Eline A. J.
Sánchez-Juan, Pascual
Rábano, Alberto https://orcid.org/0000-0001-9320-6566
Martínez, Minerva https://orcid.org/0000-0002-9036-2595
Doecke, James D. https://orcid.org/0000-0003-2863-0293
Bellomo, Giovanni https://orcid.org/0000-0003-0456-5650
Vermunt, Lisa https://orcid.org/0000-0001-7420-6384
Alcolea, Daniel https://orcid.org/0000-0002-3819-3245
Halbgebauer, Steffen https://orcid.org/0000-0002-8711-5702
in ‘t Veld, Sjors
Mattsson-Carlgren, Niklas
Veverova, Katerina https://orcid.org/0000-0002-5845-1854
Fowler, Christopher J.
Boonkamp, Lynn
Koel-Simmelink, Marleen
Hussainali, Zulaiga
Ruiters, Daimy N.
Gaetani, Lorenzo https://orcid.org/0000-0003-3967-8954
Toja, Andrea https://orcid.org/0009-0000-9500-7632
Fortea, Juan https://orcid.org/0000-0002-1340-638X
Pijnenburg, Yolande
Lemstra, Afina W.
van der Flier, Wiesje M. https://orcid.org/0000-0001-8766-6224
Hort, Jakub
Otto, Markus https://orcid.org/0000-0003-4273-4267
Hansson, Oskar https://orcid.org/0000-0001-8467-7286
Parnetti, Lucilla https://orcid.org/0000-0001-5722-3967
Masters, Colin L.
Lleó, Alberto https://orcid.org/0000-0002-2568-5478
Teunissen, Charlotte E. https://orcid.org/0000-0002-4061-0837
Del Campo Milán, Marta https://orcid.org/0000-0003-2808-3699
-
Funding
Funding for this research was provided by:
EC | Horizon 2020 Framework Programme (860197)
- License Information
-
More Information
Article History
Received: 12 July 2024
Accepted: 15 January 2025
First Online: 29 January 2025
Competing interests
: D.A. participated in advisory boards from Fujirebio-Europe, Roche Diagnostics, Grifols S.A. and Lilly, and received speaker honoraria from Fujirebio-Europe, Roche Diagnostics, Nutricia, Krka Farmacéutica S.L., Zambon S.A.U. and Esteve Pharmaceuticals S.A. L.G, participated on advisory boards for, and received writing honoraria and travel grants from Almirall, Biogen, Euroimmun, Fujirebio, Lilly, Merck, Mylan, Novartis, Roche, Sanofi, Siemens Healthineers and Teva. A.L. participated in advisory boards from Almirall, Biogen, Eisai, Fujirebio-Europe, Grifols, Novartis, Roche, Otsuka Pharmaceutical, Nutricia, Zambón, y NovoNordisk. C.E.T. has a collaboration contract with ADx Neurosciences, Quanterix, and Eli Lilly, performed contract research or received grants from AC-Immune, Axon Neurosciences, BioConnect, Bioorchestra, Brainstorm Therapeutics, Celgene, EIP Pharma, Eisai, Fujirebio, Grifols, Instant Nano Biosensors, Merck, Novo Nordisk, PeopleBio, Roche, Siemens, Toyama, Vivoryon. She is editor of Alzheimer Research and Therapy and serves on editorial boards of Medidact Neurologie/Springer, and Neurology: Neuroimmunology & Neuroinflammation. She had speaker contracts for Roche, Grifols, and Novo Nordisk. The remaining authors declare no competing interests.
